Proc Natl Acad Sci U S A. 2018 Nov 1. pii: 201814044. doi: 10.1073/pnas.1814044115. [Epub ahead of print]

Oncogenic role of SFRP2 in p53-mutant osteosarcoma development via autocrine and paracrine mechanism.

Kim H^1,2,3, Yoo S^4,5, Zhou R^6,7, Xu A⁶, Bernitz JM^1,2,3, Yuan Y^1,2,3, Gomes AM^1,2,8,9, Daniel MG^1,2,3, Su J^1,2,3,10, Demicco EG^11,12, Zhu J^4,5, Moore KA^1,2,3, Lee DF^{13,2,6,7,14,15}, Lemischka IR^1,2,3,16, Schaniel C^13,2,3,16,17.

Abstract

Osteosarcoma (OS), the most common primary bone tumor, is highly metastatic with high chemotherapeutic resistance and poor survival rates. Using induced pluripotent stem cells (iPSCs) generated from Li-Fraumeni syndrome (LFS) patients, we investigate an oncogenic role of secreted frizzled-related protein 2 (SFRP2) in p53 mutation-associated OS development. Interestingly, we find that high SFRP2 expression in OS patient samples correlates with poor survival. Systems-level analyses identified that expression of SFRP2 increases during LFS OS development and can induce angiogenesis. Ectopic SFRP2 overexpression in normal osteoblast precursors is sufficient to suppress normal osteoblast differentiation and to promote OS phenotypes through induction of oncogenic molecules such as FOXM1 and CYR61 in a β-catenin-independent manner. Conversely, inhibition of SFRP2, FOXM1, or CYR61 represses the tumorigenic potential. In summary, these findings demonstrate the oncogenic role of SFRP2 in the development of p53 mutation-associated OS and that inhibition of SFRP2 is a potential therapeutic strategy.